New drug SAR444336 takes first step in human safety trial

NCT ID NCT05876767

Completed Knowledge-focused Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 2 times

Summary

This early-phase study tested a new investigational drug called SAR444336 in 76 healthy adults to see if it is safe and how the body processes it. Participants received either the drug or a placebo as a single or repeated injection. The goal was to gather safety data before moving on to test the drug in patients with a disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SAR444336
What this could lead to: If this drug is safe, it could be tested in patients with certain diseases to see if it helps.
What could go wrong: This is a very early phase 1 study in only 76 healthy people. It is designed to check safety, not effectiveness. The drug may not work or may have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY VOLUNTEER

Contacts and locations

Locations

Investigational Site Number :5280001

Leiden, Leiden, 2333 CL, Netherlands
Investigational Site Number :5280002

Groningen, Provincie Groningen, 9728 NZ, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.